{"filing":{"accession_number":"0001356576-26-000031","cik":"0001356576","ticker":"SUPN","company_name":"SUPERNUS PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"supn-20260722.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657626000031/supn-20260722.htm"},"events":[{"id":19663,"run_id":17693,"accession_number":"0001356576-26-000031","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a press release announcing the timing and logistics for Supernus Pharmaceuticals' second quarter 2026 financial results disclosure. The company explicitly states it \"will report second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026\" and will host a conference call with President and CEO Jack Khattar and CFO Tim Dec to discuss these results. This is a standard earnings announcement disclosure under Item 2.02, material to investors as it provides notice of upcoming quarterly financial performance disclosure.","company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18814,"accession_number":"0001356576-26-000031","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release announcing the timing and logistics for Supernus Pharmaceuticals' second quarter 2026 financial results disclosure. The company explicitly states it \"will report second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026\" and will host a conference call with President and CEO Jack Khattar and CFO Tim Dec to discuss these results. This is a standard earnings announcement disclosure under Item 2.02, material to investors as it provides notice of upcoming quarterly financial performance disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T21:07:52.404116+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18814,"accession_number":"0001356576-26-000031","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release announcing the timing and logistics for Supernus Pharmaceuticals' second quarter 2026 financial results disclosure. The company explicitly states it \"will report second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026\" and will host a conference call with President and CEO Jack Khattar and CFO Tim Dec to discuss these results. This is a standard earnings announcement disclosure under Item 2.02, material to investors as it provides notice of upcoming quarterly financial performance disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T21:07:52.404116+00:00","company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","filing_date":"2026-07-22"}]}